AZN Company Profile and Key Details

NYSE : AZN

AstraZeneca

$200.08

-1.13-0.56%

Open: 10:57 AM

67.8

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

AstraZeneca PLC (AZN) stock declined over -0.56%, trading at $200.08 on NYSE, down from the previous close of $201.21. The stock opened at $201.44, fluctuating between $199.95 and $201.80 in the recent session.

Stock Snapshot

201.21

Prev. Close

310.18B

Market Cap

199.95

Day Low

30.55

P/E Ratio

6.55

EPS (TTM)

2.1

Cash Flow per Share

201.44

Open

1.55B

Number of Shares

201.8

Day High

49.82%

Free Float in %

12.54

Book Value

426.42K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	202.55	204.73	202.07	204.38	2.21M
Apr 13, 2026	202.48	203.18	200.70	202.24	1.72M
Apr 10, 2026	207.30	207.30	203.82	204.03	1.56M
Apr 09, 2026	202.64	206.50	201.97	204.99	1.24M
Apr 08, 2026	205.45	206.73	203.66	204.27	2.24M
Apr 07, 2026	198.71	202.00	196.95	200.81	2.45M
Apr 06, 2026	204.75	204.75	202.73	202.83	1.55M
Apr 02, 2026	199.78	204.34	199.23	203.49	2.05M
Apr 01, 2026	198.89	201.74	198.72	200.73	2.16M
Mar 31, 2026	194.85	197.27	193.55	197.22	2.75M
Mar 30, 2026	193.83	194.64	192.61	193.88	2.11M
Mar 27, 2026	190.88	192.97	187.95	188.42	2.76M
Mar 25, 2026	187.67	188.72	186.44	187.14	1.48M
Mar 24, 2026	182.63	186.22	182.39	185.78	1.57M
Mar 23, 2026	183.86	186.78	183.76	184.07	2.01M
Mar 20, 2026	188.14	188.40	182.62	183.60	2.07M
Mar 19, 2026	186.73	189.79	186.33	188.93	1.47M
Mar 18, 2026	190.67	190.73	187.56	188.42	1.17M
Mar 17, 2026	193.96	193.96	190.95	191.29	1.43M
Mar 16, 2026	190.81	192.51	190.54	192.01	1.78M

Contact Details

Cambridge, CB2 0AA

United Kingdom

https://www.astrazeneca.com 442 037 495000

About Company

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Stock Peers

LLY

-7.05-0.76%

Eli Lilly and Company$922.50 JNJ

2.14+0.90%

Johnson & Johnson$240.10 ABBV

3.85+1.86%

AbbVie Inc.$210.32 NVS

-1.09-0.71%

Novartis AG$153.38 MRK

-0.19-0.16%

Merck & Co., Inc.$119.96 GSK

0.24+0.41%

GSK plc$59.18 BMY

0.02+0.03%

Bristol-Myers Squibb Company$58.08 NVO

1.34+3.53%

Novo Nordisk A/S$39.32 PFE

-0.21-0.77%

Pfizer Inc.$27.13 OGN

0.16+1.87%

Organon & Co.$8.70

Company Overview

AstraZeneca PLC (NYSE:AZN) closed at $200.08 USD, losing -$1.13 (-0.56%) from the previous close of $201.21. The stock is currently mid-range between its 52-week high and low $132.32 and $212.71. With a market capitalization of about $310.18 billion, AstraZeneca PLC is classified as a mega-cap and shows lower-than-market volatility (beta ~0.28). Key stats such as the average daily volume over the past year has been around 2.37 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, None, AstraZeneca PLC operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Pascal Claude Roland Soriot, the company employs approximately 94,300 people and listed since May 12, 1993. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 3.04%, SMA50 7.55%, SMA200 25.28%). The stock’s 14-day RSI is 59.1 (neutral), while the ATR of 5.31 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -4.1% below its high and over 66.84% above its low. Average 10-day trading volume of 1.85 million shares is below the 3-month average of 3.82 million, indicating normal recent market interest.

Valuation Metrics

AstraZeneca PLC trades at a P/E ratio of 15.44, slightly below the S&P 500 average, with a price-to-sales ratio of 5.38 and a price-to-book ratio of 3.24 trading at moderately above to book value. The P/FCF stands at 29.88, also below market averages.

Dividend & Fair Value

AstraZeneca PLC last paid a dividend of 3.18 per share, this equals a trailing yield of roughly 3.72%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $418.28. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

AstraZeneca PLC generated EPS of $6.55 over the past year. Five-year average earnings growth is 22.05%. Wall Street analysts project EPS growth of 11.8% annually over the next five years. The latest quarter delivered EPS of $1.19. The next quarter is forecast at $2.49. Next year's EPS is expected at $14.05. AstraZeneca PLC earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 4.39%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 3.13% in July 25, 2024.

Shareholding & Insider Activity

AstraZeneca PLC has 1.55 billion shares outstanding. The public float is 1.54 billion shares, elevated short interest at 0.13% of float. This equals 1.98 million shares. The short ratio is 0.99 days. Institutional investors hold 16.73% of the float. Insiders own 0.0%.

Financial & Profitability Overview

Over the trailing twelve months, AstraZeneca generated $45.81B in revenue, or $14.66 per share. Gross margin was 81.95%, operating margin 17.88%, and net profit margin 13.00%. Returns are healthy, with ROA at 5.89% and ROE at 15.21%.
On valuation metrics, AstraZeneca trades at a P/E of 15.44, P/S of 5.38 and P/B of 3.24. Liquidity is tight, with a current ratio of 0.94 and quick ratio of 0.72. Operationally, the company’s inventory turnover is 1.62 and cash conversion cycle is -548.40 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.61, supported by a cash flow-to-debt ratio of 0.49.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AstraZeneca posted revenue of $45.81B, down slightly from $44.35B in the prior quarter. Gross profit was $37.54B (margin 81.95%). Operating income was $8.19B (margin 17.9%). Net income was$5.96B (EPS $1.92).
The company ended the quarter with $5.86B in cash and short-term investments, a total debt of $28.62B, and net debt of $22.78B. Total assets were $101.12B, with equity of $39.17B. Financials further reflected stability, with operating cash flow of $10.35B, free cash flow of $6.57B, and capital expenditures of - $3.78B.

Price Forecast & Outlook

Our AI price prediction model suggests that AstraZeneca PLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.5%, with price expected at $215.62 by April 28, 2026, within a range of $210.36 to $221.01 3-Month Outlook: Projected rise of 267.02%, reaching $750.11 by July 13, 2026, with a range of $748.89 to $751.49. 1-Year Outlook: Projected gain of 6.72%, with price at $218.11 by April 14, 2027, within a range of $207.18 to $225.06.

Key Takeaways

AstraZeneca PLC (NYSE:AZN) shares are flat -2.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows AstraZeneca PLC trading at a premium to the broader market with a P/E of 15.44. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $79.75, suggesting -60.98% downside. Our AI forecast model points to short-term strength (5.5% over two weeks), a medium-term rise (267.02% over three months), and a longer-term gain (6.72% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AstraZeneca PLC (AZN) stock price?

AstraZeneca PLC (NYSE: AZN) stock price is $200.08 in the last trading session. During the trading session, AZN stock reached the peak price of $201.80 while $199.95 was the lowest point it dropped to. The percentage change in AZN stock occurred in the recent session was -0.56% while the dollar amount for the price change in AZN stock was - $1.13.

AZN's industry and sector of operation?

The NYSE listed AZN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. AstraZeneca PLC designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AZN?

No Data

How AZN did perform over past 52-week?

AZN's closing price is 54.46% higher than its 52-week low of $132.32 where as its distance from 52-week high of $212.71 is -3.92%.

How many employees does AZN have?

Number of AZN employees currently stands at 94,300.

Link for AZN official website?

Official Website of AZN is: https://www.astrazeneca.com

How do I contact AZN?

AZN could be contacted at phone 442 037 495000 and can also be accessed through its website. AZN operates from 1 Francis Crick Avenue, Cambridge, CB2 0AA, United Kingdom.

How many shares of AZN are traded daily?

AZN stock volume for the day was 426.42K shares. The average number of AZN shares traded daily for last 3 months was 2.37M.

What is the market cap of AZN currently?

The market value of AZN currently stands at $310.18B with its latest stock price at $200.08 and 1.55B of its shares outstanding.

Employees	94300
Beta	0.28
Sales or Revenue	$45.81B
5Y Sales Change%	0.681%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

AZN Company Profile and Key Details

AstraZeneca

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Shareholding & Insider Activity

Technical Performance

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics